Tech-Enabled Healthcare Performance Firm, 40-Year Advisory & SaaS Platform

$5.5M

Revenue

$2.2M

SDE

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a healthcare performance-improvement and technology firm that has been operating since 1984, selling advisory services, multi-year implementation programs, digital and SaaS learning, and AI-enabled tools to hospitals, health systems, community health centers and clinic networks. The pitch to clients is that most healthcare organizations know what to fix but struggle to sustain frontline behavior change, so the Company embeds a structured multi-year model backed by proprietary IP and technology to make improvement stick. The business reports CAD $5.5M in gross revenue at a roughly 22.6% EBITDA margin, with 100% of revenue coming from U.S. customers despite the Calgary headquarters.

What makes it notable is the blend of durable client relationships, a deep proprietary content library (leadership, patient-experience and education resources), and an owned annual industry conference that functions as both a marketing channel and a community moat. Long-term engagements and repeat business drive recurring revenue, which is unusual for a consulting-adjacent firm and is what separates a genuine platform from a founder-led services shop.

The founder is running a planned succession and retirement process and is willing to remain involved as an ambassador, which matters a lot for a relationship-driven business of this age. The ideal buyer is a strategic already serving healthcare organizations who can cross-sell into this client base, or a capital-backed operator who can scale the SaaS and AI layer with operating leverage. The deal is being run by ProNova Partners under NDA, with the business name withheld until buyers are vetted.

Why we like it

Earnings quality is strong for the category: roughly $2.17M of SDE and $1.24M of EBITDA on $5.5M revenue, a ~22.6% EBITDA margin that is healthy for an advisory-plus-software model. The mix of recurring SaaS and multi-year implementation contracts should make the earnings less lumpy than a pure project-consulting shop.
The moat is real and hard to copy: 40 years of operating history, a proprietary IP and content library, and an owned annual healthcare conference that acts as a community flywheel for retention and lead generation. Competitors can sell advice, but few own a multi-year implementation methodology plus an embedded conference community.
Market tailwinds are favorable because hospitals and health systems face persistent pressure on patient experience scores, workforce retention and reimbursement tied to performance metrics. These are non-discretionary priorities that clients fund even in downturns, which supports pricing power and durability.
The operator advantage is clear for a strategic buyer: a party already serving healthcare organizations can plug this content and client base into an existing distribution engine and expand wallet share immediately. There is also operating leverage in the SaaS and AI offerings that a disciplined owner can scale with modest incremental cost.
100% U.S. revenue with long-term client engagements gives real revenue visibility and reduces customer-reacquisition cost. Recurring, relationship-based revenue in healthcare is exactly the boring, durable cash flow profile worth paying up for.

How to improve it

Audit the revenue mix in the first 90 days to separate truly recurring SaaS and renewal revenue from one-time implementation and advisory fees. Understanding the real recurring base determines both the right multiple and where to invest to grow stickier, higher-margin dollars.
Push pricing discipline and enterprise agreements with existing clients to expand wallet share, since the listing flags this as a primary opportunity. Converting multi-year engagements into enterprise-wide contracts with health systems lifts contract values without proportional delivery cost.
Invest behind the SaaS and AI-enabled products to shift delivery from labor-heavy consulting toward software with operating leverage. Every point of revenue moved from people-delivered to platform-delivered improves margin and makes the business more scalable and more valuable.
Build a repeatable enterprise sales motion to penetrate larger hospitals and multi-market health systems rather than relying on founder relationships. A dedicated sales team with named-account targeting de-risks the founder transition and accelerates top-line growth.
Formalize founder dependency reduction by documenting the methodology, codifying the IP, and transferring key client relationships during the ambassador period. This protects revenue through the transition and is the single biggest value lever for a buyer.
Monetize the annual conference more aggressively through sponsorships, higher-tier memberships, and year-round digital community engagement. The conference is already a growth engine, so turning it into a standalone recurring-revenue and lead-gen asset compounds its value.
Expand into community health centers and clinic networks, a segment the listing explicitly identifies as under-penetrated. Productizing a lower-cost offering for smaller organizations widens the addressable market without heavy custom delivery.

Diligence notes

Verify the currency and geography reality: the listing reports CAD $5.5M revenue but claims 100% U.S. customers with a Calgary HQ. Confirm actual USD revenue, FX exposure on contracts, and whether financials are stated in CAD before underwriting the multiple.
Quantify true recurring revenue versus project-based revenue, including contract terms, renewal rates, and remaining contract value. The thesis depends on the recurring base being real, so pull a customer-by-customer revenue schedule from the CIM.
Assess founder dependency and customer concentration, since a 40-year founder-led firm often carries relationships that do not transfer easily. Identify how much revenue sits with the founder personally and the top 5 to 10 clients.
Diligence the SaaS and AI claims carefully: confirm what software is actually proprietary and productized versus marketing framing on a consulting business. Review the tech stack, IP ownership, development roadmap and any third-party or AI-vendor dependencies.
Examine the conference economics as a standalone unit, including attendance trends, sponsorship revenue, cost to run, and its contribution to new client acquisition. If the conference is a loss leader dependent on the founder, model the risk to pipeline post-sale.
Clarify deal structure and valuation given the undisclosed asking price, confirming whether seller financing and an earnout can tie the founder's ambassador role to retention and transition milestones. Align the structure so the price reflects post-transition, founder-independent earnings.

Source

Originally listed on BizBuySell. View original listing →